Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 6Colonic Neoplasms 2Anus Neoplasms 2Rectal Neoplasms 1Pathologic Complete Response 1Lymphoma, Mantle-Cell 1HIV Infections 1Digestive System Diseases 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Anal Canal Carcinoma 1Adenomatous Polyposis Coli 1

Interventions

Specimen Handling 5Nivolumab 5Magnetic Resonance Spectroscopy 4pembrolizumab 3Biopsy 3dehydroftorafur 2Tomography, X-Ray Computed 2Sigmoidoscopy 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Proctoscopy 2Paclitaxel 2Mitozytrex 2Mitomycin 2Fluorouracil 2Fluorodeoxyglucose F18 2Drug Therapy 2Colonoscopy 2Carboplatin 2Capecitabine 2trastuzumab deruxtecan 1entinostat 1bintrafusp alfa protein, human 1X-Rays 1Watchful Waiting 1Taxes 1Surveys and Questionnaires 1Sentinel Lymph Node Biopsy 1Restraint, Physical 1Radionuclide Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anus Neoplasms × Colonoscopy × 90 days × Clear all
NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡